增强子结合锌指蛋白 2（EZH2）是一个潜在的治疗靶点，在肾癌细胞中受 miR-101 调控。

The enhancer of zeste homolog 2 (EZH2), a potential therapeutic target, is regulated by miR-101 in renal cancer cells.

机构信息

Laboratory of Molecular Oncology, Department of Urology, Yamagata University School of Medicine, Iida-nishi 2-2-2, Yamagata 990-9585, Japan.

出版信息

Biochem Biophys Res Commun. 2012 Jun 15;422(4):607-14. doi: 10.1016/j.bbrc.2012.05.035. Epub 2012 May 15.

DOI:10.1016/j.bbrc.2012.05.035

PMID:22609199

Abstract

We investigated a prognostic significance and the mechanism of aberrant nuclear expression of EZH2, a histone methyltransferase, in human renal cell carcinoma (RCC). We found nuclear EZH2 in 48 of 100 RCCs and it was significantly correlated with worse survival in RCC patients. We detected a decreased expression of miR-101 in 15 of 54 RCCs. We found that re-expression of miR-101 resulted in EZH2 depletion and decreased renal cancer cell proliferation. Our results show nuclear EZH2 as a prognostic marker of worse survival in human RCC, and identify miR-101 as a negative regulator of EZH2 expression and renal cancer cell proliferation.

摘要

我们研究了组蛋白甲基转移酶 EZH2 的异常核表达在人肾细胞癌（RCC）中的预后意义和机制。我们发现 100 例 RCC 中有 48 例存在核 EZH2，其与 RCC 患者的生存不良显著相关。我们在 54 例 RCC 中检测到 miR-101 的表达降低。我们发现，miR-101 的重新表达导致 EZH2 耗竭和肾癌细胞增殖减少。我们的研究结果表明，核 EZH2 是人 RCC 预后不良的标志物，并确定 miR-101 是 EZH2 表达和肾癌细胞增殖的负调节剂。